Loading...
Loading...
Athersys
ATHX dropped 52.38% to $1.30 in pre-market trading on failed trial results for ulcerative colitis.
OncoGenex Pharmaceuticals
OGXI shares fell 47.84% to $5.06 in pre-market trading after the company and Teva Pharmaceutical Industries
TEVA offered top-line survival results of the Phase III SYNERGY trial for combo with first-line docetaxel/prednisone therapy.
POZEN
POZN shares dropped 18.84% to $7.41 in pre-market trading following Friday's Complete Response Letter from the FDA.
Newmont Mining
NEM dipped 5.29% to $25.05 in pre-market trading after the company terminated its merger talks with Barrick Gold
ABX.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
